Pay in 4 interest-free payments of $6.19 Learn more
Ships within 48 hours · Estimated delivery Nov 7 - Nov 12
Dosing Schedules from Published Research Phase 2 Trial Dose Groups The Phase 2 clinical trial published in NEJM employed the following dose groups, all administered via subcutaneous injection once weekly: Scroll sideways to view the full table on mobile
Sabon, I., De Revel, G., Kotseridis, Y
CJC-1295 with DAC (Drug Affinity Complex) carries a maleimide linker that binds covalently to serum albumin, extending plasma half-life to approximately 68 days and producing a sustained GHRH-receptor signal
Some therapies like stress reduction, dietary modifications, and microbiome support may enhance BPC-157s effectiveness for comprehensive digestive restoration
Edema: reduce dose by 0.05 mg and elevate legs
